Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.
暂无分享,去创建一个
E. Domany | A. Borkhardt | D. Bercovich | G. Rechavi | S. Izraeli | C. Shochat | I. Iacobucci | C. Harrison | J. Bourquin | L. Hertzberg | M. Stanulla | H. Kempski | S. Strehl | G. Cazzaniga | A. Yoda | G. Cario | B. Bornhauser | G. Te Kronnie | S. Zeligson | L. Russell | E. Vendramini | Ithamar Ganmore | J. Chalker | R. Shiloh | Maike Schmitz | Libi Hertzberg
[1] P. D. Dal Cin,et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia , 2009, Proceedings of the National Academy of Sciences.
[2] Takashi Akasaka,et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. , 2009, Blood.
[3] R. Foà,et al. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). , 2009, Blood.
[4] M. Loh,et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia , 2009, Proceedings of the National Academy of Sciences.
[5] S. Izraeli,et al. Constitutional aneuploidy and cancer predisposition. , 2009, Human molecular genetics.
[6] S. Izraeli,et al. Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. , 2009, Blood.
[7] N. Heerema,et al. Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia , 2009, British journal of haematology.
[8] W. Evans,et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. , 2009, The Lancet. Oncology.
[9] K. Anderson,et al. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. , 2009, Blood.
[10] D. Basso,et al. Integration of genomic and gene expression data of childhood ALL without known aberrations identifies subgroups with specific genetic hallmarks , 2009, Genes, chromosomes & cancer.
[11] B. Johansson,et al. B‐cell precursor t(8;14)(q11;q32)‐positive acute lymphoblastic leukemia in children is strongly associated with Down syndrome or with a concomitant Philadelphia chromosome , 2009, European journal of haematology.
[12] K. Anderson,et al. Specific JAK 2 mutation ( JAK 2 R 683 ) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia , 2009 .
[13] W. Leonard,et al. The Role of Thymic Stromal Lymphopoietin in CD8+ T Cell Homeostasis1 , 2008, The Journal of Immunology.
[14] A. Melnick,et al. BCL6-Mediated Survival Signaling Promotes Drug-Resistance in BCRABL1- Driven Acute Lymphoblastic Leukemia , 2008 .
[15] J. Downing,et al. The Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Sub-Classification of Leukemia: Final Report on 3252 Cases from the International MILE Study Group , 2008 .
[16] G. Wainreb,et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome , 2008, The Lancet.
[17] L. Kearney,et al. Array comparative genome hybridization analysis of acute lymphoblastic leukaemia and acute megakaryoblastic leukaemia in patients with Down syndrome , 2008, British journal of haematology.
[18] Christopher B. Miller,et al. BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros , 2008, Nature.
[19] B. Johansson,et al. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. , 2008, Blood.
[20] T. Enver,et al. Initiating and Cancer-Propagating Cells in TEL-AML1-Associated Childhood Leukemia , 2008, Science.
[21] J. Błasiak,et al. DNA damage and repair in children with Down's syndrome. , 2008, Mutation research.
[22] M. Rocchi,et al. Upregulation of the SOX5 by promoter swapping with the P2RY8 gene in primary splenic follicular lymphoma , 2007, Leukemia.
[23] M. Shipp,et al. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. , 2007, Blood.
[24] Christopher B. Miller,et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia , 2007, Nature.
[25] Tomoki Ito,et al. TSLP: an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation. , 2007, Annual review of immunology.
[26] Kenny Q. Ye,et al. Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas , 2007, Proceedings of the National Academy of Sciences.
[27] S. Ziegler,et al. Thymic stromal lymphopoietin in normal and pathogenic T cell development and function , 2006, Nature Immunology.
[28] R. Spang,et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. , 2006, The New England journal of medicine.
[29] H. Lodish,et al. Active Conformation of the Erythropoietin Receptor , 2006, Journal of Biological Chemistry.
[30] Aravind Subramanian,et al. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[31] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[32] S. Constantinescu,et al. Janus Kinases Affect Thrombopoietin Receptor Cell Surface Localization and Stability* , 2005, Journal of Biological Chemistry.
[33] Dan Tsafrir,et al. Sorting points into neighborhoods (SPIN): data analysis and visualization by ordering distance matrices , 2005, Bioinform..
[34] Adam A. Margolin,et al. Reverse engineering of regulatory networks in human B cells , 2005, Nature Genetics.
[35] Ash A. Alizadeh,et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. , 2004, The New England journal of medicine.
[36] S. Ziegler,et al. Absence of an Essential Role for Thymic Stromal Lymphopoietin Receptor in Murine B-Cell Development , 2004, Molecular and Cellular Biology.
[37] T. Barrette,et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.
[38] J. Downing,et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. , 2003, Blood.
[39] Brad T. Sherman,et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.
[40] A. Teigler‐Schlegel,et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. , 2003, Blood.
[41] A. Alcover,et al. The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression , 2003, The EMBO journal.
[42] H. Lodish,et al. The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. , 2001, Molecular cell.
[43] Heinz Baumann,et al. Cloning of a receptor subunit required for signaling by thymic stromal lymphopoietin , 2000, Nature Immunology.
[44] N. Copeland,et al. Molecular cloning of a novel type 1 cytokine receptor similar to the common gamma chain. , 2000, Blood.
[45] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[46] I. Kirsch,et al. Disruption of the human SCL locus by "illegitimate" V-(D)-J recombinase activity. , 1990, Science.